Drugmakers have embraced artificial intelligence
— using computers to analyze reams of data and
then make predictions or recommendations.
Germany’s Bayer has been testing how the
technology can help diagnose complex or rare
conditions, hasten drug development and more.
The aspirin-creator has partnered with
startups and other tech companies to develop
software and apps to speed diagnosis and
guide treatment. The company is working with
hospitals, academic researchers and others to
compile everything the AI software needs to
“learn” before it analyzes a patient’s condition.
That includes information on disease causes,
symptoms and progression, plus many past
patients’ test results, doctor reports and
scanned images.BAYER USING AI TO IMPROVE DISEASE DIAGNOSIS, DRUG DESIGN
Image: Benoit Tessier